scholarly journals Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy

2019 ◽  
Vol 11 (1) ◽  
pp. 319-330
Author(s):  
Louis S. Matza ◽  
Beatrice Osumili ◽  
Katie D. Stewart ◽  
Magaly Perez-Nieves ◽  
Jessica Jordan ◽  
...  
2018 ◽  
Vol Volume 12 ◽  
pp. 971-979 ◽  
Author(s):  
Louis Matza ◽  
Kristina Boye ◽  
Jessica Jordan ◽  
Kirsi Norrbacka ◽  
Raffaella Gentilella ◽  
...  

2019 ◽  
Vol 22 (8) ◽  
pp. 806-813 ◽  
Author(s):  
Kristina S. Boye ◽  
Louis S. Matza ◽  
Katie D. Stewart ◽  
Jessica Jordan ◽  
Giovanni Biricolti ◽  
...  

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii137-ii137
Author(s):  
Gordon Chavez ◽  
Christina Proescholdt

Abstract BACKGROUND Despite the importance of Health State Utilities for health policy and medical decision making, there are no publications that provide high quality utility values estimated from glioblastoma multiforme (GBM) patients. Published health economic evaluations for GBM treatments rely on utilities determined by Garside et al. (2007), which used the standard gamble method in healthy panel members of the UK National Health System. There are no published utilities for GBM estimated from a general population sample, and there are no utility estimates whatsoever for Tumor Treating Fields (TTFields) users. METHODS We designed a study to remedy this major deficit by eliciting utilities directly from GBM patients using the EuroQol 5-Dimension (EQ-5D) survey. The EQ-5D is a widely used and NICE-recommended tool for the estimation of health state utilities. The survey is composed of a questionnaire that asks patients to specify their health state along 5 dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Statistical models provided by EuroQol’s network of researchers convert this data into health state utility estimates. RESULTS The EQ-5D questionnaire is administered to active patients using TTFields treatment during the study duration, allowing the elicitation of health preference measures for different glioblastoma health states based on: progression status (progressed vs. non-progressed), current treatments (TTFields only vs. TTFields + others) and time-from-diagnosis (0-12 months vs. > 12 months) CONCLUSION These results are important for understanding the patient preferences using TTFields treatment and communicating these preferences to decision makers. This study is the first to provide direct, high quality utility measures in glioblastoma patients using TTFields treatment.


2011 ◽  
Vol 9 (1) ◽  
pp. 119 ◽  
Author(s):  
Ning Yan Gu ◽  
Marc F Botteman ◽  
Xiang Ji ◽  
Christopher F Bell ◽  
John A Carter ◽  
...  

2005 ◽  
Vol 100 (3) ◽  
pp. 524-533 ◽  
Author(s):  
Lauren B Gerson ◽  
Nighat Ullah ◽  
Trevor Hastie ◽  
George Triadafilopoulos ◽  
Mary Goldstein

2012 ◽  
Vol 15 (4) ◽  
pp. 681-687 ◽  
Author(s):  
P. Swinburn ◽  
J. Wang ◽  
D. Chandiwana ◽  
W. Mansoor ◽  
A. Lloyd

Sign in / Sign up

Export Citation Format

Share Document